Key facts
- It has raised $17.1M; the latest was Later Stage VC in Jul 2025.
- Notable investors include Highlight Capital, Lapam Capital, Beijing Municipal Commission of Science and Technology, Beijing Zhongguancun Collaborative Innovation Investment Fund Management, Flyfot Ventures — 7 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 7 names
- ·Watchlist + deal alerts for Beijing Unicet Biotechnology
- ·The full record, as it builds
Funding rounds
No funding rounds for Beijing Unicet Biotechnology are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Beijing Unicet Biotechnology
Developer of cell-based immunological agents intended for therapeutic use. The company offers engineered γδ T cells integrated with universal CAR constructs, supported by proprietary modulation of butyrophilin pathways and scalable allogeneic manufacturing processes, serving oncology and immunology markets to access off-the-shelf cellular therapies with enhanced targeting precision, reduced production time, and broader applicability across solid and hematologic malignancies.
- Sector
- Healthcare
- HQ
- Beijing, China
- Founded
- 2018
- Website
- qhln.yswlvip.com/
- Ownership
- Privately Held (backing)
Beijing Unicet Biotechnology doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Beijing Unicet Biotechnology shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Beijing Unicet Biotechnology in its N-PORT filings yet. We sweep new filings monthly.